MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

Statement of Purpose
Guidelines for Authors
Editorial Board

Recent Issues

September 2008


Effect of Prescription Copays on Adherence and Treatment Failure with Oral Antidiabetic Medications

Increased cost sharing by patients results in the reduced use of prescription drugs. A retrospective study by the authors found that diabetic patients did not adhere to their regimens, and thus did not meet target treatment goals, if they were required to pay part of the cost of their medications.
John Barron, PharmD; Peter Wahl, MLA, MS; Maxine Fisher, PhD; and Craig Plauschinat, PharmD, MPH

Health Care and Law

Vaccine Declinations Present New Challenges for Public Health

Immunizations can protect large numbers of people in a community — even those who have not been inoculated. However, the reluctance of growing numbers of people to receive vaccinations for themselves and their children raises the risk of reducing “herd immunity,” which can lead to widespread infection in a population.
Robert I. Field, JD, MPH, PhD


Universal Health Care in America: Can the Massachusetts Model Work Nationwide?

Every citizen 18 years of age and older in Massachusetts is required to obtain health insurance. This article describes the state’s progress and discusses how it might influence proposals for health care reform offered by the two presidential candidates.
Miriam Reisman

Meeting Highlights

Digestive Disease Week and American Diabetes Association

Therapies covered include balsalazide (Colazal) and infliximab (Remicade) for ulcerative colitis; infliximab/methotrexate and certolizumab pegol (Cimzia) for Crohn’s disease; and glucose-lowering strategies, as well as a combination of sitagliptin (Januvia) and metformin (Glucophage), for diabetes.
Walter Alexander

Pharmaceutical Approval Update

Topics include clevidipine (Cleviprex) for reducing blood pressure; repaglinide/ metformin (PrandiMet) for improving glycemic control; and difluprednate ­ophthalmic emulsion (Durezol) for treating inflammation and pain after ocular surgery.
Marvin M. Goldenberg, PhD, RPh, MS



Eight Tech Trends

David Nash, MD, MBA, describes eight emerging ­technology trends that are transforming markets and businesses and may soon be coming to a P&T committee near you.
David Nash, MD, MBA

Medication Errors

The Truth about Hospital Formularies, Part 2

In part 2 of a two-part article, Matthew Grissinger, RPh, FASCP, explains how P&T committee members can be negatively influenced when they encounter myths and misconceptions about ­formularies.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Democrats Getting Their Medicare Ducks in a Row for Next Year

Stephen Barlas discusses how taxpayers might be able to save almost $90 million per year if a bill were passed to eliminate the inflated prices for Part D Medicare benefits.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From Cleviprex to Xenazine, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.

Drug Forecast

Ixabepilone (Ixempra), a Therapeutic Option for Locally Advanced or Metastatic Breast Cancer

Dr. Egerton reviews ixabepilone (Ixempra) for metastatic or locally advanced breast cancer.
Nancy Egerton, PharmD, BCOP